1National Institute for Health and Care Excellence. Depression: The Treatment and Management of Depression in Adults (update). Clinical Guideline 91. NICE, 2009
2Cleare, A, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29: 459–525.
3de Diego-Adelino, J, Portella, MJ, Puigdemont, D, Perez-Egea, R, Alvarez, E, Perez, V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord 2010; 120: 221–5.
4Rhebergen, D, Beekman, AT, De, GR, Nolen, WA, Spijker, J, Hoogendijk, WJ et al. Trajectories of recovery of social and physical functioning in major depression, dysthymic disorder and double depression: a 3-year follow-up. J Affect Disord 2010; 124: 148–56.
5Bauer, M, Pretorius, HW, Constant, EL, Earley, WR, Szamosi, J, Brecher, M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70: 540–9.
6Dunner, DL, Rush, AJ, Russell, JM, Burke, M, Woodard, S, Wingard, P, Allen, J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006; 67: 688–95.
7Dunlop, BW, Kelley, ME, Aponte-Rivera, V, Mletzko-Crowe, T, Kinkead, B, Ritchie, JC, et al. Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. Am J Psychiatry 2017; 174: 546–56.
8Gaynes, BN, Warden, D, Trivedi, MH, Wisniewski, SR, Fava, M, Rush, AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60: 1439–45.
9Conway, CR, George, MS, Sackeim, HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry 2017; 74: 9–10.
10Haddad, PM, Talbot, PS, Anderson, IM, McAllister-Williams, RH. Managing inadequate antidepressant response in depressive illness. Br Med Bull 2015; 115: 183–201.
11Arnow, BA, Steidtmann, D, Blasey, C, Manber, R, Constantino, MJ, Klein, DN, et al. The relationship between the therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic depression. J Consult Clin Psychol 2013; 81: 627–38.
12DeRubeis, RJ, Cohen, ZD, Forand, NR, Fournier, JC, Gelfand, LA, Lorenzo-Luaces, L. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One 2014; 9: e83875.
13Weck, F, Grikscheit, F, Jakob, M, Hofling, V, Stangier, U. Treatment failure in cognitive-behavioural therapy: therapeutic alliance as a precondition for an adherent and competent implementation of techniques. Br J Clin Psychol 2015; 54: 91–108.
14Scottish ECT Audit Network. Annual Report 2015: A Summary of ECT in Scotland for 2014. Scottish ECT Audit Network, 2015.
15Pae, CU, Lim, HK, Han, C, Neena, A, Lee, C, Patkar, AA. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1153–63.
16Wiersma, JE, Van Schaik, DJ, Hoogendorn, AW, Dekker, JJ, Van, HL, Schoevers, RA, et al. The effectiveness of the cognitive behavioral analysis system of psychotherapy for chronic depression: a randomized controlled trial. Psychother Psychosom 2014; 83: 263–69.
17Goss, AJ, Kaser, M, Costafreda, SG, Sahakian, BJ, Fu, CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013; 74: 1101–7.
18Kleeblatt, J, Betzler, F, Kilarski, LL, Bschor, T, Kohler, S. Efficacy of off-label augmentation in unipolar depression: a systematic review of the evidence. Eur Neuropsychopharmacol 2017; 27: 423–41.
19Strejilevich, SA, Martino, DJ, Igoa, A, Manes, F. Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 2011; 23: E2–3.
20Bobo, WV, Voort, JL, Croarkin, PE, Leung, JG, Tye, SJ, Frye, MA. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety 2016; 33: 698–710.
21National Institute for Health and Care Excellence. Repetitive Transcranial Magnetic Stimulation for Depression. NICE Interventional Procedure Guidance (IPG542) NICE, 2015.
22National Institute for Health and Care Excellence. Vagus Nerve Stimulation for Treatment Resistent Depression. NICE Interventional Procedure Guidance (IPG 330). NICE: 2009.
23Aaronson, ST, Sears, P, Ruvuna, F, Bunker, M, Conway, CR, Dougherty, DD, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry 2017; 174: 640–8.
24American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (5th edn) (DSM-5). APA, 2013.
25Cuijpers, P, Berking, M, Andersson, G, Quigley, L, Kleiboer, A, Dobson, KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013; 58: 376–85.
26Morriss, R, Garland, A, Nixon, N, Guo, B, James, M, Kaylor-Hughes, C, et al. Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. Lancet Psychiatry 2016; 3: 821–31.